๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
INTRODUCTION
Erythroderma is defined as generalized erythema and scaling involving >80% of the body surface area (BSA). However, it does not represent a defined entity, but rather is a striking and severe clinical presentation that can arise from a variety of diseases. Most commonly, erythroderma is due to generalization of pre-existing dermatoses (such as psoriasis or atopic dermatitis), drug reactions, or cutaneous T cell lymphoma (CTCL). Although up to 50% of the patients have a history of more localized skin lesions prior to the onset of the erythroderma, identification of the underlying disease process represents one of the most complex challenges in dermatology. Sustained efforts during longitudinal evaluation may lead to the precise identification of the etiology. In approximately one-quarter of the patients, no specific etiology is found, and these cases are called โidiopathic erythrodermaโ.
Attention should also be focused on the potential systemic complications of acute erythroderma. Hypothermia, peripheral edema, and loss of fluid, electrolytes and albumin with subsequent tachycardia and cardiac failure are serious threats to the erythrodermic patient. In addition, chronic erythrodermas may be accompanied by cachexia, diffuse alopecia, palmoplantar keratoderma, nail dystrophy, and ectropion.